Brief: GW Pharma and Otsuka announce results in first of three Sativex phase 3 cancer pain trials
08/01/2015 12:00
Jan 8 (Reuters) - GW Pharmaceuticals PLC GWP.L : * GW Pharmaceuticals and Otsuka announce results in first of three Sativex(R) phase 3 cancer pain trials * Primary endpoint did not show a statistically significant difference for sativex compared with placebo in reducing pain * In first trial, Sativex did not meet primary endpoint of demonstrating statistically significant difference from placebo * Says the safety profile of sativex in the phase 3 trial was consistent with previous studies in this patient population * Says overall, Sativex was well tolerated * Says results of this third trial are expected towards the end of 2015 * Source text for Eikon ID:nGNXVCLKNa * Further company coverage GWP.L ((Bengaluru Newsroom; +1 646 223 8780))